Latest Actos news
Pioglitazone Cuts Diabetes Risk After Ischemic Stroke, TIA
by modernClinician Editorial Team
For insulin-resistant patients with recent ischemic stroke or transient ischemic attack, pioglitazone is associated with reduced risk of diabetes, according to a study published online July 27 in Diabetes Care.
Long-Term Pioglitazone Safe, Effective for NASH, T2DM
by modernClinician Editorial Team
For patients with prediabetes or type 2 diabetes mellitus and nonalcoholic steatohepatitis, long-term pioglitazone is safe and effective, according to a study published online June 21 in the Annals of Internal Medicine.
CYP2C8, SLCO1B1 Variants Impact Response to Rosiglitazone
by modernClinician Editorial Team
Genetic variants in CYP2C8 and SLCO1B1 impact the therapeutic response to rosiglitazone in patients with type 2 diabetes, according to a study published online June 6 in Diabetes Care.
Pioglitazone Linked to Increased Risk of Bladder Cancer
by modernClinician Editorial Team
For patients with type 2 diabetes newly treated with antidiabetic drugs, use of pioglitazone is associated with an increased risk of bladder cancer, with duration-response and dose-response correlations, according to a study published online March 30 in The BMJ.
Editor's Recommendations
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes 
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD 
Type 2 Diabetes Linked to Worse Menopausal Symptoms 
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer 
Pioglitazone Has Limited Effect in Lipoatrophic Diabetes 
Exenatide, Pioglitazone Effective for Poorly Controlled T2DM Monthly Specialist Briefings
Stay Connected
